Goldman Sachs
LUCD icon

Goldman Sachs’s Lucid Diagnostics LUCD Stock Holding History

Goldman Sachs’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$279K Sell
242,658
-46,617
-16% -$59.3K ﹤0.01% 5931
2025
Q4 		$315K Sell
289,275
-270,879
-48% -$303K ﹤0.01% 5839
2025
Q3 		$566K Buy
560,154
+251,476
+81% +$275K ﹤0.01% 5433
2025
Q2 		$355K Buy
308,678
+222,376
+258% +$287K ﹤0.01% 5354
2025
Q1 		$129K Buy
86,302
+22,727
+36% +$27.3K ﹤0.01% 5735
2024
Q4 		$52K Buy
+63,575
New +$56.1K ﹤0.01% 5842
2022
Q1 		– Sell
-24,540
Closed -$132K – 6759
2021
Q4 		$132K Buy
+24,540
New +$199K ﹤0.01% 6047

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Goldman Sachs's LUCD Position: Q1 2026 in Review

Goldman Sachs reduced its Lucid Diagnostics (LUCD) stake by 16% in Q1 2026, selling an estimated $59.3K and leaving 242,658 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #5931.

Goldman Sachs first reported a position in LUCD in Q4 2021 and has held it in 7 quarters since. The position peaked at $566K in Q3 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Goldman Sachs held 242,658 shares of Lucid Diagnostics worth $279K as of Q1 2026.
  • Goldman Sachs sold 46,617 Lucid Diagnostics shares in Q1 2026, an estimated $59.3K.
  • Lucid Diagnostics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5931 holding.
  • Goldman Sachs first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 7 quarters since.
  • Goldman Sachs's Lucid Diagnostics position peaked at $566K in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.